Alerta

SAFETY TOOLS FOR DECISION SUPPORT RECOMMENDATIONS MADE TO USERS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS

Resumen de: US20260000323A1

Systems and method are described for determining if a decision support recommendation is to be presented to a user for treatment of a diabetic state, including receiving a plurality of input data items impacting a diabetic state of a user of continuous glucose monitor, the input data items serving as input data to a process for determining a decision support recommendation; assigning a reliability level to each of the input data items; calculating a reliability metric based on the reliability levels assigned to each of the input data items; determining a decision support recommendation based on the process and the input data and presenting the decision support recommendation to the user on a user interface only if the reliability metric exceeds a threshold.

DETECTION OF CHANGES IN PATIENT HEALTH BASED ON GLUCOSE DATA

Resumen de: US20260000322A1

This disclosure is directed to systems and techniques for detecting change in patient health based upon patient data. In one example, a medical system comprising processing circuitry communicably coupled to a glucose sensor and configured to generate continuous glucose sensor measurements of a patient. The processing circuitry is further configured to: extract at least one feature from the continuous glucose sensor measurements over at least one time period, wherein the at least one feature comprises one or more of an amount of time within a pre-determined glucose level range, a number of hypoglycemia events, a number of hyperglycemia events, or one or more statistical metrics corresponding to the continuous glucose sensor measurements; apply a machine learning model to the at least one extracted feature to produce data indicative of a risk of a cardiovascular event; and generate output data based on the risk of the cardiovascular event.

NEUROMODULATION SYSTEM TO INDUCE CHANGES IN GLYCEMIC REGULATORY SYSTEM PLASTICITY

Resumen de: US20260000895A1

Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. However, issues with compliance, side effects and permanent anatomical alterations provide a need for an alternative therapy to modulate a peripheral nerve, such as the vagus nerve, in a manner that causes a plastic change in the glycemic regulatory system, with or without the involvement of the central nervous system (CNS), that changes the activity of an organ and thereby changing the activity of that organ. Low energy vagus nerve neuromodulation has potential as a new treatment for type 2 diabetes mellitus by inducing plasticity of the body's glycemic regulatory system with low energy transient stimulation. This will allow for effective use of a small implantable pulse generator that requires infrequent, or no, charging during the life of the device.

Protable device and method for non-invasive measurement of the level of physiological values sPortable device and method for non-invasive estimation of the level of

Resumen de: US20260000363A1

A portable device and method for non-invasive estimation of the level of physiological values such as blood glucose and blood cholesterol, comprising a central processing unit (1) which includes connections to: a signal emitter which emits signals via electrodes in contact with the skin, which, when processed by a bioimpedance microcontroller and said central processing unit (1), provide values such as hydration, body mass index, bone index; a digital optical sensor (4) which allows calculation of the blood oxygen value, heart rate and temperature; and enzymatic sensors (5) which determine the quantity of glucose or lactate; said central processing unit (1) calculating the physiological values on the basis of an automatic learning algorithm that has been trained with a set of clinical history data from a group of patients for whom at least values of bioimpedance, temperature, oxygen and heart rate are available.

SELF-INSERTING TROCARLESS ANALYTE-SENSING CANNULA

Resumen de: US20260000831A1

The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.

CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE

Resumen de: EP4671882A2

The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: WO2024175636A1

The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances, - at least one and preferably two infusion sets connectable to said device for infusing a said substance to said person; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit and thereby infused into the body of the person via said or a respective infusion set, wherein said certain amount is chosen in accordance with the measured glucose concentration, wherein said controller is arranged to determine a slope of the measured glucose concentration, and wherein the time unit per which the certain amount is supplied is dependent on said slope.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: WO2024179895A1

The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying insulin and glucagon, - at least two infusion sets; - at least one sensor for measuring a glucose concentration in the blood of said person, and - a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.

SYSTEM FOR REGULATING THE CONCENTRATION OF GLUCOSE IN THE BLOOD OF A PERSON

Resumen de: WO2024175639A1

The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances to said person, - at least one and preferably two infusion sets connectable to said device; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.

SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR ADAPTIVE BIO-BEHAVIORAL CONTROL (ABC) IN DIABETES

Resumen de: WO2024178261A1

A method, system, and computer readable medium for implementing the Adaptive Bio-Behavioral Control concept, which allows for bi-directional, human-machine co-regulation of metabolic disorders, such as diabetes mellitus. The Adaptive Bio-Behavioral Control concept may encompass, but is not limited thereto, three modules: a) a Physiological Adaptation Module which processes a user's historical data to estimate a personalized model of the user's glucose metabolism and to calculate suggested insulin-dosing parameters; b) a Behavioral Adaptation Module which assists the user's adaptation to the treatment action by determining a plurality of actionable information and risk assessments based on the user's glucose monitoring records; and c) a Replay Module which computes a simulation of effects from hypothetical changes to the user's treatment or behavior based on a personalized model of the user's glucose metabolism.

BIOELECTRONICS BASED ON FUNCTIONALIZED PROTEINS

Nº publicación: EP4671378A1 31/12/2025

Solicitante:

UNIV VILNIUS [LT]
Vilnius University